Equities Analysts Offer Predictions for ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Research analysts at B. Riley upped their FY2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Thursday, January 2nd. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of $1.00 per share for the year, up from their prior forecast of $0.99. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.79) per share.

ARWR has been the subject of several other reports. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Sanford C. Bernstein dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. Finally, Piper Sandler cut their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Hold” and an average target price of $43.33.

Arrowhead Pharmaceuticals Stock Up 0.9 %

NASDAQ ARWR opened at $19.67 on Monday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -3.92 and a beta of 0.97. The company has a 50 day moving average of $21.03 and a 200-day moving average of $22.56. Arrowhead Pharmaceuticals has a 1-year low of $17.05 and a 1-year high of $39.83.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Values First Advisors Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $52,000. Meeder Asset Management Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 4,629.2% in the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 3,333 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 788 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $149,000. Finally, Quarry LP raised its holdings in Arrowhead Pharmaceuticals by 54.5% during the 2nd quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 3,000 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director William D. Waddill sold 3,748 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the completion of the transaction, the director now owns 44,125 shares of the company’s stock, valued at $966,337.50. This represents a 7.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the sale, the insider now owns 272,122 shares in the company, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 146,473 shares of company stock worth $2,937,847 over the last quarter. Corporate insiders own 4.50% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.